Literature DB >> 8085435

Co-localization of beta/A4 and cystatin C in cortical blood vessels in Dutch, but not in Icelandic hereditary cerebral hemorrhage with amyloidosis.

J Haan1, M L Maat-Schieman, S G van Duinen, O Jensson, L Thorsteinsson, R A Roos.   

Abstract

Based on the recent discovery of co-localization of beta/A4 and cystatin C in cortical blood vessels of patients with cerebral hemorrhages due to sporadic amyloid angiopathy and patients with Alzheimer's disease we investigated the presence of these two proteins in the cortical blood vessels of patients suffering from hereditary cerebral hemorrhage with amyloidosis of the Dutch (n = 11) and the Icelandic (n = 2) type. The brains of three patients with sporadic cerebral amyloid angiopathy were also investigated. Blood vessels of the Dutch patients clearly showed immunostaining with beta/A4 as well as with cystatin C antibodies, whereas the blood vessels of Icelandic patients showed only staining with cystatin C. In one of the three sporadic amyloid angiopathy patients co-localization was shown as well. The co-localization of mutated beta/A4 with normal cystatin C in the Dutch patients suggests that cystatin C deposition occurs secondarily to beta/A4 deposition. This is probably also the case in sporadic amyloid angiopathy and Alzheimer's disease. Cystatin C deposition may play a role in the development of cerebral hemorrhages and leukoencephalopathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8085435     DOI: 10.1111/j.1600-0404.1994.tb02648.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  12 in total

1.  Elevation of cystatin C in susceptible neurons in Alzheimer's disease.

Authors:  A Deng; M C Irizarry; R M Nitsch; J H Growdon; G W Rebeck
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines.

Authors:  Belen Tizon; Susmita Sahoo; Haung Yu; Sebastien Gauthier; Asok R Kumar; Panaiyur Mohan; Matthew Figliola; Monika Pawlik; Anders Grubb; Yasuo Uchiyama; Urmi Bandyopadhyay; Ana Maria Cuervo; Ralph A Nixon; Efrat Levy
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

Review 3.  The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses.

Authors:  Laura Morelli; Ramiro Llovera; Sandra Ibendahl; Eduardo M Castaño
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

Review 4.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

5.  Overexpression of human cystatin C in transgenic mice does not affect levels of endogenous brain amyloid Beta Peptide.

Authors:  Monika Pawlik; Magdalena Sastre; Miguel Calero; Paul M Mathews; Stephen D Schmidt; Ralph A Nixon; Efrat Levy
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

6.  Complexes of amyloid-beta and cystatin C in the human central nervous system.

Authors:  Weiqian Mi; Sonia S Jung; Haung Yu; Stephen D Schmidt; Ralph A Nixon; Paul M Mathews; Fabrizio Tagliavini; Efrat Levy
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 7.  Protective mechanisms by cystatin C in neurodegenerative diseases.

Authors:  Sebastien Gauthier; Gurjinder Kaur; Weiqian Mi; Belen Tizon; Efrat Levy
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

8.  Cystatin C in Alzheimer's disease.

Authors:  Gurjinder Kaur; Efrat Levy
Journal:  Front Mol Neurosci       Date:  2012-07-06       Impact factor: 5.639

Review 9.  The Positive Side of the Alzheimer's Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1.

Authors:  Lidia Ciccone; Chenghui Shi; Davide di Lorenzo; Anne-Cécile Van Baelen; Nicolo Tonali
Journal:  Molecules       Date:  2020-05-23       Impact factor: 4.411

10.  Alterations of CSF cystatin C levels and their correlations with CSF Αβ40 and Αβ42 levels in patients with Alzheimer's disease, dementia with lewy bodies and the atrophic form of general paresis.

Authors:  Xiao-Mei Zhong; Le Hou; Xin-Ni Luo; Hai-Shan Shi; Guo-Yan Hu; Hong-Bo He; Xin-Ru Chen; Dong Zheng; Yue-Feng Zhang; Yan Tan; Xue-Jun Liu; Nan Mu; Jian-Ping Chen; Yu-Ping Ning
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.